|Description||EGT1442 is a potent and selective SGLT2 inhibitor with IC50 value of 5.6 μM /2 nM in SGLT1 /SGLT2 respectively. It significantly prolonged the median survival of SHRSP rats. It attenuates blood glucose and HbA(1c) levels and prolongs the survival of stroke-prone rats in db/db mice. It showed favorable properties both in vitro and in vivo and could be beneficial to the management of type 2 diabetic patients. It was developed by Theracos and in clinic phase 1 trials.|
|Solubility||Soluble to 35mg/mL in CD3OD|
|Application||EGT1442 showed favorable properties and could be beneficial to the management of type 2 diabetic patients.|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Quantity||Grams to Kilograms|
|Boiling Point||671.0±55.0 °C | Condition: Press: 760 Torr|
|Density||1.41±0.1 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr|
|Current Developer||EGT1442 was developed by Theracos and in clinic phase 1 trials.|
Phlorizin is a 2'-glucoside of phloretin. It belongs to the group of dihydrochalcones, a type of flavonoids.
LX-4211 is a potent dual SGLT2/1 inhibitor; Antidiabetic agents.
Ipragliflozin is a highly potent and selective SGLT2 inhibitor and has little and NO potency for SGLT1/3/4/5/6.
LIK066 is a potent Sodium-glucose transporter 1 and Sodium-glucose transporter 2 inhibitor originated by Novartis Pharmaceuticals Corporation IC50 value is 22.0...
EGT1442 is a potent and selective SGLT2 inhibitor with IC50 value of 5.6 μM /2 nM in SGLT1 /SGLT2 respectively. It significantly prolonged the median survival o...
Atigliflozin is a selective sodium-glucose co-transporter subtype 2 (SGLT2) inhibitor. It has antihyperglycemic activity and is used as an antihyperglycaemic dr...
hloretin is a dihydrochalcone, a type of natural phenols, which shows beneficial effects on diabetes.
Tofogliflozin is an experimental drug for the treatment of diabetes mellitus and is being developed by Chugai Pharma in collaboration with Kowa and Sanofi. It i...
PF-04971729, a potent and selective inhibitor of the sodium-dependent glucose cotransporter 2, is currently in phase 2 trials for the treatment of diabetes mell...
Dapagliflozin (2S)-1,2-propanediol, hydr
Dapagliflozin (2S)-1,2-propanediol, hydrate is a selective, orally active inhibitor of the renal sodium-glucose co-transporter type 2 (SGLT2). It is in developm...
TA-1887 is a selective Sodium Glucose Cotransporter 2 Inhibitor with pronounced antihyperglycemic effects in high-fat diet-fed KK (HF-KK) mice. It may be used f...
Canagliflozin hemihydrate is a highly potent and selective inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90...
Canagliflozin is a sodium/glucose cotransporter 2 (SGLT2) inhibitor. Canagliflozin has been shown to dose dependently reduce calculated renal threshold for gluc...
Mizagliflozin is a sodium-glucose transporter inhibitor. It is expected to improve postprandial hyperglycemia by suppressing glucose absorption from the intesti...
Tofogliflozin(CSG-452) hydrate is a potent and highly specific sodium/glucose cotransporter 2(SGLT2) inhibitor with Ki values of 2.9, 14.9, and 6.4 nM for human...
Empagliflozin is a potent and selective SGLT-2 inhibitor with IC50 of 3.1 nM, exhibits >300-fold selectivity over SGLT-1, 4, 5 and 6.
Dapagliflozin(BMS512148) is a selective, orally active inhibitor of the renal sodium-glucose co-transporter type 2 (SGLT2) is in development for the treatment o...
KGA2727 is a selective and potent SGLT1 inhibitor for the treatment of diabete. Its inhibition constant (Ki) values of 97 and 13,600 nM for human (h) SGLT1 and ...